Senior insider sale
President & CEO at ULTRAGENYX PHARMACEUTICAL INC. — senior position signals high conviction
$1.97M
45K shares
What this filing means
KAKKIS EMIL D plans to sell 45K shares of ULTRAGENYX PHARMACEUTICAL INC. valued at approximately $1.97M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 2/28/2025ACC: 0002007317-25-000222
DirectorOfficer· President & CEO
Since Mar 2026
45K
Shares to sell
$1.97M
Approx. market value
25K
Acquired (3 months)
1
Planned
2 completed
Securities Acquired — Last 3 Months4
STOCK BONUS
CASH
4/29/2022
290.00STOCK BONUS
CASH
9/11/2019
5KSTOCK BONUS
CASH
8/28/2017
1.45KFOUNDERS SHARES
CASH
4/27/2010
18.26KTotal acquired25K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
4/29/2022 | STOCK BONUS CASH | 290.00 | — |
9/11/2019 | STOCK BONUS CASH | 5K | — |
8/28/2017 | STOCK BONUS CASH | 1.45K | — |
4/27/2010 | FOUNDERS SHARES CASH | 18.26K | — |
| Total | 25K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
11.73K
Market value
$495.3K
12/30/2024
—Completed
Units to sell
8.27K
Market value
$413.6K
12/10/2024
Planned — Approximate Date
NASDAQPlanned
Units to sell
25K
Market value
$1.06M
2/28/2025
Total
Units
45K
Value
$1.97M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
12/30/2024 | 11.73K | $495.3K | — | Completed |
12/10/2024 | 8.27K | $413.6K | — | Completed |
| Planned — Approximate Date | ||||
2/28/2025 | 25K | $1.06M | NASDAQ | Planned |
| Total | 45K | $1.97M | ||